NANOBIOTIX: Reclassification and New Patent for JNJ-1900 (NBTXR3)

Nanobiotix announces two key advancements regarding its product candidate JNJ-1900 (NBTXR3). This radioenhancer has been reclassified as a drug by European health authorities, aligning its regulatory status with that of the United States and other major markets.

This reclassification, based on recent data on its mechanism of action, facilitates global regulatory harmonization and supports future international strategies. At the same time, Nanobiotix has filed an application for a new composition patent, thereby strengthening the product's intellectual property rights.

JNJ-1900 (NBTXR3) continues its global clinical development, including a Phase 3 trial in head and neck cancer. The company is committed to advancing the product for patients awaiting new therapeutic options.